

Nike Sport Sole - Clinical Investigation Protocol

Nike Sport Sole

NCT04787640

Cosmesis

CONFIDENTIAL DOCUMENT

Document Sign-off Information			
Document No.	CIP2020010830	Change Notice Number	N/A
Author	[REDACTED]	Signature and Date [REDACTED] 07.07.2020	
Reviewer	[REDACTED]	Signature and Date [REDACTED] 07.07.2020	
Approver	[REDACTED]	Signature and Date [REDACTED] 07.07.2020	
Refer to electronic approval of document for complete approval information.			
Revision Information			
Revision	Change Context		
2.00	Project:	[REDACTED]	
	Project Manager:		
	Product Manager:		

This document contains information that is confidential and proprietary to Össur. Neither this document nor the information therein may be reproduced, used or distributed to or for the benefit of any third party without the prior consent of Össur.

This document is uncontrolled when printed unless indicated otherwise.

Sponsor

VP of Medical Office and Clinical Affairs
Össur Iceland ehf
Grjótháls 3-5
110 Reykjavík, Iceland

Coordinating Investigator

Sponsor's Statement: I have reviewed and approved this CIP in its entirety and agree to sponsor its implementation

Sponsor:	Date of Signature:
<i>Electronical Approval of Document, front page</i>	<i>Electronical Approval of Document, front page</i>

Monitor #1	Össur hf	Clinical testing and research specialist
Monitor #2	Össur hf	Clinical testing and research specialist
Monitor #3	Össur hf	Medical Director Prosthetics
Monitor #4	Össur hf	Clinical Documentation Specialist
Co-investigator:	Össur hf	Product Designer
Co-investigator:	Össur hf	Product Designer
Co-investigator:	Össur hf	Project Manager
Co-investigator:	Össur hf	Biomechanical Engineer
Co-investigator	Össur hf	Sr. Product Designer

Co-investigator		Össur hf	Sr. Industrial Designer
Co-investigator		Nike	Footwear designer
Co-investigator		Nike	Footwear designer
Co-investigator		MCOP	CPO
Local Principal Investigator:		Össur hf	Director of Clinical Education

Investigational site:

MCOP, Silver Spring Prosthetic Clinic		
Local Principal Investigator:		CPO
Local Co-Investigator:		CPO

Table of Contents

1	How to Refer to This Document	6
2	Summary.....	6
3	Changes from Previous Revision	8
3.1	Changes for Revision 1.00.....	8
3.2	Changes for Revision 2.00.....	8
4	Abbreviations	9
5	Investigational Device.....	10
6	Justification for the Design of the Clinical Investigation	13
7	Objectives and Hypotheses.....	14
8	Design of the Clinical Investigation	15
8.1	General	15
8.2	Investigational Device(s) and Comparator(s)	15
8.3	Subjects	16
8.4	Procedures.....	17
	i) Recruitment	17
	ii) Test procedure.....	17
		18
8.5	Compensation.....	18
		18
		18
8.6	Responsibilities	18
8.7	Study monitoring and Oversight.....	19
9	Investigational Device Accountability	19
10	Statistical Considerations	20
10.1	Statistical design and procedures	20
10.2	Sample size calculation	20
10.3	Additional statistical matters.....	20
11	Amendments and Deviations from the Protocol (CIP).....	20
11.1	Amendments.....	20
11.2	Deviations	20
12	Statement of Compliance	21
13	Ethical Considerations	21
13.1	Anticipated clinical benefits	21
13.2	Device related risk	21
13.3	Risk of Study (To Patient)	22
13.4	Risk Mitigation.....	22
13.5	Risk-to-Benefit Rationale	22
13.6	IRB/REB/REC Review and Communications.....	22
13.7	Vulnerable populations	23
13.8	Informed Consent	23
13.9	Participant confidentiality – Data management.....	23

14	Evaluation of Adverse Events and Device Deficiencies	23
14.1	Definitions of adverse events, effects and deficiencies	23
14.2	Reporting procedures	24
14.3	Suspension or premature termination of the clinical investigation.....	24
15	Publication Policy	25
16	References	26

Tables

Table 1	Identification and Description of the Investigational Device.....	10
Table 2	Technical and functional features.....	12
Table 3	Endpoints, test methods and hypotheses.....	14
Table 4	Inclusion/Exclusion criteria	16
Table 5	Visit schedule and procedures	17

1 How to Refer to This Document

[0] CIP2020010830, Clinical Investigation Protocol

2 Summary

Device(s) being tested:	<p>Nike Sport Sole (pre-market).</p> <p>For simplification the device under evaluation in this clinical investigation will be referred to as “investigational device” throughout this document.</p>	
Instruments and equipment:	<p>Instruments for data collection will include the following:</p> <ul style="list-style-type: none"> - Questionnaire - User journal - Picture/Video <p>Equipment required for each amputee subject:</p> <ul style="list-style-type: none"> • Pen/pencil • Detailed protocol • Printed out instruments and instructions (case report forms, in-house questionnaire) • Logbook/Notebook • Stopwatch/Phone • Measuring tape • Investigational device: Nike Sport Sole (2 versions; traction sole and spike pad) and Cheetah Xceed (components as applicable) • Tools for fitting 	
Subjects recruited:	Inclusion criteria:	Exclusion criteria:
10 subjects	50Kg< body weight < 116Kg	50Kg> body weight > 116Kg
	<u>K-level:</u> K3 and K4	Users with socket problems
	<u>Amputation level:</u> Unilateral, bilateral Trans-tibial, trans-femoral	Users with cognitive impairment
	Currently using running prosthesis with the option to connect to the components	

	the investigational device is compatible to	
	<u>Minimum build height:</u> Distance from ground to socket adapter needs to be 318 mm or more	Younger than 18 years old
	Comfortable and stable socket fit	
	Willing and able to participate in the study and follow the protocol	
Procedures:	<p>There are two scheduled study events. At the initial visit, the first study event, for each subject a researcher qualified to obtain informed consent will seat the subject and proceed as described in chapter 13.8 Informed consent.</p> <p><u>Visit 1.</u></p> <p>Prior to fitting the investigational device, the subjects will be asked to provide feedback on their current prescribed running prosthesis, by filling in a set of questionnaires, run outside, both on level and rolling terrain and attach and detach the sole to blade. Investigators will record name and category of their current device and type of sole used. Picture will be taken of the current device from side and front.</p> <p>The users will then be fitted to the investigational device within the standard methods of prosthetic fitting, alignment, introduction, training and walking on various terrain. Subjects will be asked to provide feedback on the investigational device by filling in same sets of questionnaires and perform the same tasks. Users will be handed a journal to fill out information regarding their sport activities during the next 6-8 weeks while using the investigational device.</p> <p><u>Visit 2.</u></p> <p>The second event will take place 6-8 weeks later. When the subjects arrive at the clinic, investigators will take pictures of the investigational device (and IDs) from side and front, review subjects journal and the wear and tear of the investigational device will be evaluated. Alignment will also be reviewed. Subjects will be asked to once again, fill in the same sets of questionnaires as during the first visit and perform the same set of tasks. At last, subjects will be re-fitted to their previous prescribed device, same tasks and questionnaires will once again be repeated.</p>	


3 Changes from Previous Revision

3.1 Changes for Revision 1.00

Initial release, 20200327.

3.2 Changes for Revision 2.00

Hypothesis A rephrased and acceptance criteria aligned (Table 3 page 16). Wear/Tear scoring sheet added to Appendix 17.1 (page 30).



4 Abbreviations

ADE	Adverse Device Effect
AE	Adverse Event
AR	Adverse Reaction
BL	Baseline
CA	Competent Authority
CEP	Clinical Evaluation Plan
CER	Clinical Evaluation Report
CI	Co-Investigator
COI	Coordinating Investigator
CIB	Clinical Investigator's Brochure
CIP	Clinical Investigation Plan
CIR	Clinical Investigation Report
CRF	Case Report Form
CRO	Clinical Research Organisation
CT	Clinical Trial
CTA	Clinical Trial Authorisation
EC	Ethics Committee (see IEC, IRB, REB and REC)
EDS	Electronic Data capture Service
FU	Follow-Up
GCP	Good Clinical Practice
CIB	(Clinical) Investigator Brochure
ICF	Informed Consent Form
IDMF	Investigational Device Management Form
IEC	Independent Ethics Committee
IFU	Instructions For Use
IRB	Independent/Institutional Review Board
LCI	Local Co-Investigator
LPI	Local Principal Investigator
PI	Principle Investigator
PIS	Participant Information Sheet
REB	Research Ethics Board
REC	Research Ethics Committee
SAE	Serious Adverse Event
SADE	Serious Adverse Device Event
SOP	Standard Operating Procedure
SOTA	State-Of-The-Art
SRA	Sponsor Research Assistant
USADE	Unanticipated Serious Adverse Device Effect

5 Investigational Device

Table 1 Identification and Description of the Investigational Device

Summary description of the investigational device and its intended purpose:	The investigational device is the Nike Sport Sole which is an accessory for a medical device. The Nike Sport Sole is attachable and detachable to the foot blade of the CE marked, commercially available, running prosthesis, Cheetah Xceed. The investigational device has not been marketed yet.
Manufacturer of the investigational device:	Össur hf. Grjóthals 5 110 Reykjavík Iceland
Name or number of the model/type, including software version and accessories, if any, to permit full identification:	Nike Sport Sole (no product numbers yet)
Traceability during and after the investigation:	Investigation Device Management Form (IDMF) will be used to track the use of each device within the clinical investigation using the foot serial number as the sole itself is an accessory.
Intended purpose of the investigational device in the proposed clinical investigation:	Intended purpose of the investigational device in the proposed clinical investigation is within the intended purpose as described above. See following chapters on the intended purpose of the investigational device in the proposed clinical investigation for details.
The populations and indications for which the investigational device is intended:	The device is part of a prosthetic system targeted for lower extremity amputees (bi- or unilateral) who participate in professional or recreational sports, i.e. long- and short distance running, sprinting and jumping.
Description of the investigational device:	See Table 2 below for descriptions of device features and their relation to the investigation. The Nike Sport Sole comes in two different versions, Nike traction sole and Nike spike pad. Both versions are easily attachable and detachable to the foot blade of the running specific prosthetic foot, Cheetah® Xceed. Both sole versions consist of a rubber traction sole with a soft foam core. The Nike spike pad consists of a spike sole with a soft foam core and should be used when running on tartan track. Both sole versions are attached in the same way to the carbon foot blade. The devices slide onto the carbon foot blade and are connected by pulling a strap of the sole over an attachment piece (medallion) that is connected to the foot blade. Additionally, there are attachment clips on the side clamp on the foot blade. The Cheetah Xceed prosthetic blade has been designed to translate the functionality of Össur's high performance blades to the need of everyday sports. The device features a longer toe lever for enhanced push off. The device is made from a single piece carbon spring with a proximal pyramid adapter bolted to the top of the blade.

	<p>The device can be used with both trans-femoral and trans-tibial users. Bi- and unilateral.</p> <p>The investigational device is Class I, a low-risk product, and is a further development of a well-established technology.</p> <p>Exo-prosthetic devices are by their nature non-invasive. The investigational device is a non-sterile, reusable (i.e. non-disposable), single user device, which is used as part of prosthetic system.</p> <p>The end users of the Nike Sport Sole are professional and recreational athletes. This device should only be used in conjunction with the recommended Össur prosthetic sport feet.</p> <p>The device does not incorporate, as an integral part, a substance or human blood derivative referred to in Section 7.4 of Annex I of 93/42/EEC, amended by 2005/50/EEC. It is manufactured without utilizing tissues of animal origin as referred to in Directive 2003/32/EC.</p>
Summary of the necessary training and experience needed to use the investigational device:	<p>Training requirements for subjects and procedures relating to fitting and use of a device will for all general purposes be equivalent to the training and procedures required for using a market ready, CE-marked device of a similar type.</p> <p>The device should be supplied and fitted by a certified CPO/CO/CP.</p>
Specific medical or surgical procedures involved in the use of the investigational device:	N/A

Table 2 Technical and functional features

#	Feature
1	Traction sole
2	Spike sole
3	Attachment to foot blade: Pulling a strap of the sole over an attachment piece (medallion)

6 Justification for the Design of the Clinical Investigation

Running Specific Feet are based on the original Flex-Foot design using the energy storage and release function as the main design feature. Running specific prosthetic feet are intended for running and jogging. They all have similar design features such as a C-shaped spring carbon fiber foot plate that absorbs and returns energy when load is applied deflecting the carbon. In order to accommodate the running pattern which does not show a double stance phase as compared to walking, the Running Specific products do not feature a heel spring but directly load the C-shape spring at initial contact. The Running Specific Feet are usually equipped with additional accessory parts such as a traction sole or spike pad for smoother and more natural rollover.

The investigational device, the Nike Sport Sole, is an accessory for the Cheetah Xceed running prosthetic foot. Cheetah Xceed has already been placed on market and bears a CE mark, but the Nike Sport Sole is an upgraded Nike Sole design and the objective of this clinical investigation is to evaluate the observed wear and tear of the soles after 6-8 week usage among other usability aspects.

Preclinical testing

Variety of tests and activities have been carried out to verify the safety and performance of the investigational device.

The device was tested on a Cheetah Xceed blade in a cyclic and static test machine. The test involves static and cyclic loading on the device. For the cyclic testing the device was tested for 700,000 cycles at 2.5 kN load during each cycle. This cyclic testing is equivalent to a unilateral amputee running a total of 1,750km on the device. This is also equivalent to 41.6 marathons. The device passed this test.

Based on the intended use of the device, as it is not intended to be used directly on skin, the outcome of the risk analysis and that vendors have supplied verification that the device contains no materials of concern, biocompatibility testing was not necessitated.

Based on the results of these tests, calculations, specifications, and design verification and validation activities it is considered justifiable to use the device for human subjects.

7 Objectives and Hypotheses

The primary objective of this study is to evaluate the observed wear and tear of the new Nike Sport Sole after 6-8 weeks usage among other usability aspects compared to subjects current prescribed running prosthesis/sole combination.

No clinical claims are to be evaluated.

No risks or anticipated adverse device effects (ADE) are to be assessed.

The hypothesis and endpoints are specified in **Table 3**.

Table 3 Endpoints, test methods and hypotheses

	Hypothesis	Test Method	Endpoint	Acceptance Criteria
A	The wear/tear of the Nike Sport Sole is acceptable.	Visual inspection score /observation	Inspection score	Pass: Inspection score ≥ 3 for any Sole Items (A-D)* Fail: Inspection score < 3 for any Sole Items (A-D)* All soles must pass
Exploratory (Usability)				
E1	Ease of detaching sole from blade	Self-report / in-house questionnaire	Change in scoring between prescribed device and investigational device	NA
E2	Ease of attaching sole to blade	Self-report / in-house questionnaire	Change in scoring between prescribed device and investigational device	NA
E3	Weight of sole	Self-report / in-house questionnaire	Change in scoring between prescribed device and investigational device	NA
E4	Aesthetics of sole	Self-report / in-house questionnaire	Change in scoring between prescribed device and investigational device	NA
E5	Size/envelope/geometry of device (foot + sole)	Self-report / in-house questionnaire	Change in scoring between prescribed device and investigational device	NA

*Sole Items in Wear/Tear Scoring Sheet in Appendix

8 Design of the Clinical Investigation

8.1 General

The test will be a single group prospective within subject comparison design. Amputees are a small proportion of the general population. The population group specified in the inclusion/exclusion criteria is a further subsample of amputees.

Investigational activities will be conducted at MCOP Silver Spring Prosthetic Clinic (2421 Linden Lane, Silver Spring Md, 20910) [REDACTED]

For practical reasons, i.e. to achieve statistical power, it is therefore more feasible to use within-subject comparison rather than creating study arms to compare. Furthermore, as mobile amputees generally have and use a prosthetic device for their daily activities, within-comparison is feasible comparing to the subject's previous device.

As stated above the primary endpoint is visual inspection of wear and tear of the Nike Sport Soles, see **Table 3**, and the secondary endpoints are exploratory and only regarding usability.

Drop-outs and withdrawals will not be replaced.

See chapter 10.2 Sample size calculation and **Table 3** for analysis of variables.

Instruments for data collection will include the following:

- Questionnaire
- User journal
- Picture/Video

Equipment required for each amputee subject:

- Pen/pencil
- Detailed protocol
- Printed out instruments and instructions (Case report forms, in-house questionnaire)
- Logbook/Notebook
- Stopwatch/Phone
- Measuring tape
- Investigational device: Nike Sport Sole (2 versions; traction sole and spike pad) and Cheetah Xceed (components as applicable).
- Tools for fitting

The equipment used does not require specific monitoring, maintenance or calibration procedures.

8.2 Investigational Device(s) and Comparator(s)

As previously mentioned, the Nike Sport Sole is an accessory for the running prosthesis, Cheetah Xceed which is not a prosthesis for daily living activities, it's a prosthesis used by recreational athletes during their sports activities. The subjects will therefore be asked to use the investigational device as their primary device for running and other sport activities for 6-8 weeks. Individual exposure will differ between subjects. The comparator device will not be used within the timeframe of the investigation. Subjects will evaluate and provide feedback on their exposure of the comparator prior to them being fitted to the investigational device.

The comparator device will be subjects current prescribed running prosthesis, with proximal adapter and a sport sole. It has the same intended use as the investigational device. Furthermore, it is indicated for the same condition and population group.

The subject will be using the remaining part of their current prosthetic system with the investigational device, as it was used with the comparator device.

No other device, medication or intervention will be used.

15 subjects are to be enrolled; therefore 30 investigational devices will be used (each subject provided with both versions of the Nike Sport Sole, traction sole and spike pad). All subjects will also be provided with Cheetah Xceed running prosthesis (already a marketed product).

8.3 Subjects

All subjects will be dispositioned as follows:

- Screen Failure: Subject did not pass screening procedures, not called in for clinical visit;
- Candidate for enrollment: Passed screening procedures, accepts to come in for clinical visit;
- Enrolled: Subject signs informed consent;
- Fitted: Subject leaves the clinic on the investigational device;
- Discontinued: Candidate for enrollment or enrolled subject whose participation ended because they withdrew consent, were withdrawn by the investigator, were lost to follow up, or died.

Table 4 Inclusion/Exclusion criteria

Inclusion: Only patients with the following characteristics are eligible for study entry:	Exclusion: Patients with the following characteristics are not eligible for study entry:
50Kg< body weight < 116Kg	50Kg> body weight > 116Kg
<u>K-level:</u> K3 and K4	Users with socket problems
<u>Amputation level:</u> Unilateral, bilateral Trans-tibial, trans-femoral	Users with cognitive impairment
Currently using running prosthesis with the option to connect to the components the investigational device is compatible to	Younger than 18 years old
Minimum build height: Distance from ground to socket adapter needs to be 318 mm or more.	
Comfortable and stable socket fit	
Willing and able to participate in the study and follow the protocol	

A subject can withdraw from participation at any time, at his/her discretion, and this will not have any consequences for the participant's treatment. In such cases a report stating reasons for discontinuation of the participant shall be prepared by the LPI/CI. No further investigational procedures concerning the subject will be conducted, except for a statement explaining the reason for withdrawal, including but not limited to: interacting or interviewing the subject in order to obtain data on him/her; obtaining additional private information on the subject by either observing the subject or collecting or receiving such information from any source.

The LPI/CI can withdraw the participant from the trial at any time. The reasons shall be documented. There are no pre-specified criteria for discontinuation of participants from the trial. The discontinuation of participants in the trial will not result in replacement with new participants. If withdrawal is due to problems related to the investigational

device the participant will be asked for permission to follow the status/condition outside the clinical investigation. The follow-up will be individualized.

Subjects will be enrolled at the clinic, the investigational site that they were contacted from.

The total time period required to implement the clinical investigation is expected to be 3 months. Each individual subject is expected to participate in the clinical investigation for 6-8 weeks. The estimated time needed to include this number (enrollment period) is 2 weeks.

8.4 Procedures

i) Recruitment

Potential subjects will be identified from the customer base of the Local Principal Investigator (LPI). LPI evaluates, based on previous experience of interaction with and servicing of patients, if a potential participant is cognitively capable. If a potential participant fits the inclusion and exclusion criteria the LPI will contact them via telephone. During the telephone call the LPI will verify if they are interested in participating in a study. If interest is expressed at this point, they will answer some screening questions and if the eligibility criteria are met an appointment will be made for the clinical visit and signing of the ICF. Questions relating to the duration of the study, number of clinical visits required, and the investigational device will be answered.

Potential risk of participating in the investigation will be explained to the subject at this point to the candidate for enrolment.

The LPI will communicate to the study monitor the number of users he has identified that meet the inclusion criteria and are willing to participate.

ii) Test procedure

There are two scheduled study events. At the initial visit, the first study event, for each subject a researcher qualified to obtain informed consent will seat the subject and proceed as described in chapter **13.8 Informed consent**.

Visit 1.

Prior to fitting the investigational device, the subjects will be asked to provide feedback on their current prescribed running prosthesis, by filling in a set of questionnaires, run outside, both on level and rolling terrain and attach and detach the sole to blade. Investigators will record name and category of their current device and type of sole used. Picture will be taken of the current device from side and front.

The users will then be fitted to the investigational device within the standard methods of prosthetic fitting, alignment, introduction, training and walking on various terrain. Subjects will be asked to provide feedback on the investigational device by filling in same sets of questionnaires and perform the same tasks. Users will be handed a journal to fill out information regarding their sport activities during the next 6-8 weeks while using the investigational device.

Visit 2.

The second event will take place 6-8 weeks later. When the subjects arrive at the clinic, investigators will take pictures of the investigational device (and IDs) from side and front, review subjects journal and the wear and tear of the investigational device will be evaluated. Alignment will also be reviewed. Subjects will be asked to once again, fill in the same sets of questionnaires as during the first visit and perform the same set of tasks. At last, subjects will be re-fitted to their previous prescribed device, same tasks and questionnaires will once again be repeated.

Table 5 Visit schedule and procedures

	Recruitment phase: 2 weeks prior to baseline	Visit 1	Visit 2 (6-8 weeks later)
Potential subjects identified, fitting inclusion/exclusion criteria, by LPI from customer database	X		
LPI calls potential subjects and screens by telephone	X		
Subject signs ICF		X	
Questionnaires and running tasks administered on prescribed device		X	X
Questionnaires and tasks administered on investigational device		X	X
Subject fitted with investigational device and receives training according to standard treatment		X	
Subject fitted back to prescribed device.			X

For each subject there are two scheduled visits to the study site and questionnaires/tasks/measurements administered two times during the course of the study.

8.5 Compensation

8.6 Responsibilities

Sponsor Principal Investigator (Coordinating investigator)

- Identify sites
- Investigate possible vigilance cases/SAEs
- Train and explain the protocol to the sites

Monitor

- Monitor trial
- Collect data
- Analyze results
- Write report

Co-Investigator

- Collect Data
- Analyze results
- Write report
- Assist in conduct of trial procedures at investigators' site
- Assist in fitting users with trial device (and back to their prescribed prosthesis, if applicable)
- For Össur athletes: Co-Investigator (product designer) will also handle phone call communication along with local principal investigator

Local Principal Investigator at site

- Screen subjects
- Explain trial to participants
- Responsible for obtaining informed consent from test subjects
- Conduct all trial procedures at investigators' site
- Fit users with trial device (and back to their current prosthesis, if applicable)

Local Principal Investigator for Össur athletes

- Screen subjects
- Explain trial to participants
- Responsible for obtaining informed consent from test subjects
- Follow up phone call after 6-8 weeks, additional calls will be made if needed

8.7 Study monitoring and Oversight

The study monitor(s) will monitor the study to ensure all procedures are followed correctly and according to the study protocol. The study monitor will gather and review all study data and inform the LPI of missing data or nonconformities to the study protocol.

The study monitors and LPI/PI/CI will maintain communication on a minimum biweekly basis, via telephone and email. The LPI/PI/CI will provide the study monitors with information of all scheduled study visits.

9 Investigational Device Accountability

The investigational device will be provided as needed for the study population. Devices will not be packaged but will be labeled according to FDA regulatory requirements. Subjects will not be blinded.

The LPI will keep records documenting the receipt, use and return of the investigational device in the Investigational Device Management Form, including:

- Date of receipt
- ID of each investigational device
- Date of use
- Subject ID
- Date of device return
- Date of return of unused, expired or malfunctioning investigational devices, as applicable

10 Statistical Considerations

10.1 Statistical design and procedures

The dataset will be assessed with descriptive statistics only, comparing the means and variance for the two data points: prior-evaluation (prescribed device) and post-evaluation (investigational device). Acceptance criteria for the data, as applicable, is defined in **Table 3 Endpoints, test methods and hypotheses**. Subgroup analysis will not be performed as no subgroups are defined.

10.2 Sample size calculation

A convenience sample of 15 subjects are expected to complete the procedures. The investigational device, the Nike Sport Sole, is an accessory for the running prosthesis, Cheetah Xceed. This is a prosthesis only used by recreational athletes during their sports activities, not as a daily living prosthesis. This is a very specific group of the amputee population. Sample of 15 subjects is expected to provide good input into the use of the investigational device.

For pass/fail criteria, see **Table 3 Endpoints, test methods and hypotheses**.

10.3 Additional statistical matters

There is no provision for interim analysis and no criteria for early termination of the clinical investigation on statistical grounds.

Any deviations from the statistical plan provided in this protocol will have to be approved by the sponsor and the reasons for the deviation reported in the clinical investigational report. Drop outs and withdrawn participants will be included in the data analysis for the procedures that they completed. They will be grouped together and compared to the group that finished the protocol. Any statistical differences of the two groups will be reported. If the participants have not provided any data, they will not be included in the data analysis. No particular information will be excluded from the statistical analysis and tests, as described above.

11 Amendments and Deviations from the Protocol (CIP)

11.1 Amendments

Any amendments to this protocol must be first approved by the sponsor and PI, or LPI for single site studies, and then be evaluated by the IRB and, where appropriate regulatory authorities, before being implemented.

For non-substantial changes (e.g. minor logistical or administrative changes, change of monitor(s), telephone numbers, renewal of insurance) not affecting the rights, safety and well-being of human subjects or not related to the clinical investigation objectives or endpoints, a simple notification to the IRB and, where appropriate, regulatory authorities can be sufficient.

11.2 Deviations

Investigators are not allowed to deviate from this protocol without a formal approval from the IRB, if the deviation affects subject's rights, safety and wellbeing, or the scientific integrity of the clinical investigation. Any such deviation from the protocol is to be documented in detail and the report sent to the IRB.

Under emergency circumstances, deviations from the protocol to protect the rights, safety and well-being of human subjects may proceed without prior approval of the sponsor and the IRB. Such deviations shall be documented and reported to the sponsor and the IRB as soon as possible.

Investigators can request for an approval from the sponsor for a deviation if the deviation does not affect subject's rights, safety and wellbeing, or the scientific integrity of the clinical investigation.

In case of a deviation from this protocol taking place without prior approval from the sponsor, and IRB as applicable, it shall be reported to the sponsor within 24 hours of LPI knowledge of the deviation. The LPI responsible for the

deviation is to send a report to the sponsor no later than five days after the deviation was reported. The report shall include:

- Reason for deviation
- When deviation took place
- Circumstances of the event
- Identification of all subjects affected by the deviation, if any
 - Details how each subject is affected, e.g. rights, safety or wellbeing
- Details how this deviation might affect the scientific integrity of the clinical investigation

The sponsor and the IRB will evaluate any deviations that take place without prior approval on a case-by-case basis. If the deviation affects subject's rights, safety and wellbeing, and the scientific integrity of the clinical investigation the LPI shall be disqualified from further participation in the clinical investigation.

12 Statement of Compliance

The clinical investigation is sponsored by Össur Iceland ehf.

It shall be conducted:

- in accordance with the ethical principles that have their origin in the Declaration of Helsinki
- in compliance with the ISO 14155 International Standard
- in compliance with any regional or national legislations, as applicable

The clinical investigation shall not commence until the required approval from the IRB, and regulatory authority as applicable, has been obtained.

Any additional requirements imposed by the IRB or regulatory authority shall be followed, as applicable.

13 Ethical Considerations

13.1 Anticipated clinical benefits

A patient using the investigational device may or may not benefit clinically from using the device vis-a-vis using another sport sole for a running prosthesis commercially available. Compared to not using a sport sole for a running prosthesis the patient will benefit significantly in terms of mobility and ability to live independently. Further on the user will be trained on a new prosthetic component to experience the unprecedented functionality of the new component to mitigate the known deficiencies associated with his amputation. Within the test he/she will be trained on restoring physiological movement pattern closer to those of non-amputees.

Additionally, the benefit for the user during the testing is that he/she helps in developing a new sport sole for a running prosthesis.

13.2 Device related risk

Each device designed and manufactured by Össur is subjected to thorough risk assessment, analysis and control, with failure mode effect analysis and hazard analysis, according to QM1673 Risk Management process, based on ISO 14971 (Risk Management for Medical Devices).

Foreseeable adverse events and anticipated adverse device effects, together with their likely incidence are expected to be in line with the data provided above. Mitigation beyond standard clinical practice and the information provided in the IFU for the device is not required. This also applies to potential treatment of harms stemming from these events or effects; standard clinical practice and IFU statements will be followed.

13.3 Risk of Study (To Patient)

At each visit an LPI/PI/CI, a certified CPO/CO/CP or clinician, will be present to ensure the safety of the participants. The study adds no additional risk other than the risks identified above. Subjects will use the trial device as their primary prosthesis in the same manner as they would normally do on their current prosthesis. Thus, they are not required to do anything different from their routine clinical visit for acquiring a new sport sole for a running prosthesis and their daily living activities between study visits.

13.4 Risk Mitigation

For each device designed by Össur risk mitigation is part of the design process according to ISO 14971 [3][4]. Furthermore, each participant fitted with sport sole for a running prosthesis for the first time, or an upgraded/adjusted version of the device, will be trained by a fully qualified professional until the user can demonstrate sufficient understanding of the product operation and demonstrate minimum ability level in its operation. This process is the same as the usual training process deployed for normal fitting of a sport sole for a running prosthesis.

As part of the training process, the participant will be informed on the risks inherent in using a sport sole for a running prosthesis in an uncontrolled environment. Moreover, the participant will be provided with the product literature (e.g. Information for User), as well as being informed and trained on how to use the product.

13.5 Risk-to-Benefit Rationale

The development of a sport sole for a running prosthesis is controlled by a multi-level verification and validation processes before being authorized for field testing and subsequent release. The Design & Verification process execution, coupled with the risk management and control strategy deployed for Nike Sport Sole ensure that the risks associated with use of the device in typical daily living conditions does not exceed risks level associated with the operation of any such device under similar conditions. The investigational device is intended to provide traction and thereby a good grip to the surface the users are running on.

The residual risks of the investigation and the investigational device are minimal and are significantly out weighted by the benefits of participating in the investigation.

13.6 IRB/REB/REC Review and Communications

The study protocol (CIP), informed consent form, and other study documentation forms require IRB review and approval. Communication to and from the IRB shall be directed from or to the primary Össur contact, [REDACTED]

██████████, the Study Monitor. Continuous communication will be maintained between Össur and the IRB, as required. Moreover, communication will be maintained between the LPI/PI/CI and the IRB, as required.

13.7 Vulnerable populations

No vulnerable populations will be enrolled.

13.8 Informed Consent

The Local Principal Investigator, or any researcher qualified, will obtain from the subject, written signed informed consent form to his/her inclusion in the study, after explaining the rationale for and the details of the study, the risks and benefits of alternative treatments, and the extent of the subject's involvement. The subject will receive a copy of the informed consent.

The subjects will be informed that their participation is voluntary and that they can withdraw from participation at any time, at his/her discretion and this will not have any consequences for the participant's treatment.

In case the information on the ICF changes, and subjects need to be provided with new information, the LPI will contact each subject by phone and explain the new information as required.

Subjects that for any reason are unable to provide informed consent will not be enrolled in the study.

13.9 Participant confidentiality – Data management

Subjects will be assigned a random study identification (ID) number and a random investigational device (identified by the study serial number).

When recording video care will be taken not to include the face or other identifiable features, if they are accidentally captured, they will be blurred or blackened.

Confidentiality of all relevant subject feedback and information will be maintained through use of the identifying number only, in all documentation. The study sponsor, Össur, will remain the sole owner of the study data. A list connecting the ID to the subject's name will be stored in a password secured file until the end of the study at which point it will be destroyed. Only investigators involved in the trial will have access to this information.

The screening form will be in paper format and will be stored by the PI in a locked container. All documents will be collected by Study Monitor and/or PI.

A Clinical Investigation Report (CIR) will be generated by Medical Office. The report will be stored with the device technical file within Össur Quality Management System, along with the unlinked data and all accompanying investigational documents, according to the R&D and Quality documentation procedures. Subjects participating in the study can have access to the results, on demand, when the CIR is internally published.

Study results, data, and documentation will be stored for a minimum of 5 years.

14 Evaluation of Adverse Events and Device Deficiencies

For a list of foreseeable adverse events and anticipated adverse device effects, together with their likely incidence, mitigation or treatment see chapter 13.2 above and Hazard Analysis [3][4].

14.1 Definitions of adverse events, effects and deficiencies

An adverse event (AE) is any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users or other persons, whether or not related to the investigational medical device.

An adverse device effect (ADE) is any adverse event related to the use of an investigational medical device, including events resulting from insufficient or inadequate instructions for use, operation, malfunction, etc.

A serious/severe adverse event (SAE) is an AE that:

- Is life-threatening or fatal

- requires or prolongs hospitalization
- results in permanent impairment of a body function
- or results in permanent damage to a body structure.

A serious/severe adverse device effect (SADE) is an adverse device effect that has resulted in any of the consequences characteristic of a SAE.

An anticipated serious adverse device effect (ASADE) is an effect which by its nature, incidence, severity or outcome has been identified in the risk management for the device.

An unanticipated adverse device effect (UADE) is a serious adverse effect on health or safety of participants caused by the device if not previously identified in nature, severity, or degree of incidence in the protocol (CIP) or the risk analysis for the device.

A device deficiency (DD) is the inadequacy of a medical device with respect to its identity, quality, durability, reliability, safety or performance. Device deficiencies include malfunctions, use errors, and inadequate labelling.

A use error (UE) is an act or omission of an act that results in a different medical device response than intended by the manufacturer or expected by the user.

See ISO 14155:2011 for details.

14.2 Reporting procedures

All device related adverse events will be investigated. Adverse events that are serious, unanticipated and (possibly) device related shall be reported to the sponsor by telephone as soon as possible. The complete adverse event investigation form shall be faxed to the sponsor within 24 hrs. Within ten days the Sponsor will report to the IRB and FDA. Any serious device related adverse event will lead to the immediate termination of the trial. In this case all participants will be contacted immediately and advised to stop using the investigational device. An appointment will be made for them to return the trial device.

Participants will be provided the contact information of the investigator and told to call them in the event of an adverse event. Furthermore, an investigator will contact them weekly to check up on any problems. The participants will keep their previous **sport sole for a running prosthesis** and will be free to use it if they experience any problems with the trial device.

The investigator shall supply a copy of the complete adverse event investigation form, together with a cover letter to the IRB when events are judged to be serious, unanticipated and (possibly) device related.

[REDACTED]

[REDACTED]

[REDACTED]

Any device deficiencies that did not lead to an adverse event but could have led to a medical occurrence

- if either suitable action had not been taken,
- if intervention had not been made, or
- if circumstances had been less fortunate,

shall be reported according to the same procedure as if an ADE had taken place, specified above.

14.3 Suspension or premature termination of the clinical investigation

The sponsor/principal investigator, the IRBs, and the regulatory authorities can decide about investigation continuation. The clinical investigation can be suspended or prematurely terminated if the serious adverse device effects are considered disproportionately large compared to the possible benefits of the intervention. If the investigation is terminated or suspended all participants will be informed and appropriate follow-up will be assured. If sponsor/principal investigator terminates or suspends the investigation the relevant IRBs/REBs/RECs and regulatory authorities will be provided with a detailed written explanation of the termination or suspension.


The sponsor/principal investigator can upon completion of the analysis of the reason(s) for a suspension decide to lift the suspension, when the necessary corrective actions have been implemented. The investigators, IRBs/REBs/RECs, and relevant regulatory authorities will be notified and provided with the relevant data supporting the decision.

Breaking of blinding will not be relevant in this trial, since group allocation is visible.

15 Publication Policy

16References

Internal Document References:

[1]	
[2]	
[3]	
[4]	
[5]	